Clinical Trials
5 trialsNCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
NCT01208051 2021-07-15
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00287287 2020-06-12
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
University of Kentucky
Phase 2 Completed
NCT01254617 2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1 Completed
NCT01166035 2010-07-20
TEXO
Medical University Innsbruck
Phase 1/2 Unknown